share_log

EF Hutton Maintains Buy on ISpecimen, Lowers Price Target to $4.25

Benzinga Real-time News ·  Sep 23, 2022 10:52

EF Hutton analyst Constantine Davides maintains iSpecimen (NASDAQ:ISPC) with a Buy and lowers the price target from $5.5 to $4.25.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment